AR035429A1 - Kit y composicion farmaceutica que contienen compuestos quimioterapeuticos - Google Patents
Kit y composicion farmaceutica que contienen compuestos quimioterapeuticosInfo
- Publication number
- AR035429A1 AR035429A1 ARP020100400A ARP020100400A AR035429A1 AR 035429 A1 AR035429 A1 AR 035429A1 AR P020100400 A ARP020100400 A AR P020100400A AR P020100400 A ARP020100400 A AR P020100400A AR 035429 A1 AR035429 A1 AR 035429A1
- Authority
- AR
- Argentina
- Prior art keywords
- active ingredient
- chemotherapeutic compounds
- approximately
- compounds
- paclitaxel
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000000973 chemotherapeutic effect Effects 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 4
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un kit que comprende: a) un primer componente que contiene una o más formas de dosificación unitaria orales de un ingrediente activo, conteniendo cada unidad aproximadamente 50 mg a aproximadamente 200 mg. del ingrediente activo, en donde el ingrediente activo es un compuesto seleccionado de la fórmula (1) o una sal o éster farmacéuticamente aceptable de dicho compuesto, en donde R1 se selecciona entre el grupo que consiste en -H, CH3 y -CH2OH y R2 es -CH3; y b) un segundo componente que contiene un frasco o una serie de frascos, conteniendo cada frasco una única dosis de solución inyectable o múltiples dosis de solución inyectable, conteniendo cada dosis como ingrediente activo aproximadamente 30 mg. a aproximadamente 400 mg de paclitaxel. Los compuestos de fórmula (1) son inhibidores del ciclo celular y tienen potente actividad terapéutica anticancerígena. El paclitaxel también es útil en terapias para el cáncer. La combinación de estos compuestos quimioterapéuticos es particularmente útil en el tratamiento de cánceres de mama, colon, recto, pulmón, útero y próstata. Composiciones farmacéuticas que comprenden dichos compuestos quimioterapéuticos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26787401P | 2001-02-09 | 2001-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035429A1 true AR035429A1 (es) | 2004-05-26 |
Family
ID=23020488
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100400A AR035429A1 (es) | 2001-02-09 | 2002-02-07 | Kit y composicion farmaceutica que contienen compuestos quimioterapeuticos |
ARP140104645A AR098745A2 (es) | 2001-02-09 | 2014-12-12 | Composición, kit y uso de compuestos quimioterapéuticos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104645A AR098745A2 (es) | 2001-02-09 | 2014-12-12 | Composición, kit y uso de compuestos quimioterapéuticos |
Country Status (17)
Country | Link |
---|---|
US (1) | US6548531B2 (es) |
EP (1) | EP1359979B1 (es) |
JP (1) | JP4128872B2 (es) |
KR (1) | KR100542069B1 (es) |
CN (1) | CN1265786C (es) |
AR (2) | AR035429A1 (es) |
AT (1) | ATE324145T1 (es) |
AU (1) | AU2002246080B2 (es) |
BR (1) | BR0206954A (es) |
CA (1) | CA2435921C (es) |
DE (1) | DE60210926T2 (es) |
DK (1) | DK1359979T3 (es) |
ES (1) | ES2261648T3 (es) |
MX (1) | MXPA03007036A (es) |
PT (1) | PT1359979E (es) |
WO (1) | WO2002064214A2 (es) |
ZA (1) | ZA200305967B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072085A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
CA2447335C (en) * | 2001-05-15 | 2011-01-04 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of viral infections |
WO2002094271A1 (en) * | 2001-05-15 | 2002-11-28 | Faulk Pharmaceuticals, Inc. | Targeted delivery of bioaffecting compounds for the treatment of cancer |
WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
US20030139373A1 (en) * | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
DK2301531T3 (en) | 2005-02-18 | 2018-07-30 | Abraxis Bioscience Llc | COMBINATIONS AND WAYS FOR ADMINISTRATING THERAPEUTIC SUBSTANCES AND COMBINATION THERAPY |
LT2552415T (lt) | 2010-03-29 | 2016-12-27 | Abraxis Bioscience, Llc | Vėžio gydymo būdai |
EP2552439B1 (en) | 2010-03-29 | 2022-07-20 | Abraxis BioScience, LLC | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
NZ706745A (en) | 2010-06-04 | 2017-01-27 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
KR102325778B1 (ko) | 2016-11-15 | 2021-11-12 | 노파르티스 아게 | HDM2-p53 상호작용 억제제에 대한 용량 및 요법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
US6080777A (en) * | 1992-01-31 | 2000-06-27 | The Trustees Of Columbia University In The City Of New York | Taxol as a radiation sensitizer |
CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
WO1994004541A2 (en) * | 1992-08-12 | 1994-03-03 | The Upjohn Company | Protein kinase inhibitors and related compounds combined with taxol |
ES2203111T3 (es) | 1998-03-17 | 2004-04-01 | F. Hoffmann-La Roche Ag | Maleimidas bisindol sustituidas para la inhibicion de proloferacion celular. |
US6268398B1 (en) * | 1998-04-24 | 2001-07-31 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
-
2002
- 2002-01-23 US US10/055,451 patent/US6548531B2/en not_active Expired - Lifetime
- 2002-02-01 JP JP2002564006A patent/JP4128872B2/ja not_active Expired - Lifetime
- 2002-02-01 DE DE60210926T patent/DE60210926T2/de not_active Expired - Lifetime
- 2002-02-01 ES ES02714140T patent/ES2261648T3/es not_active Expired - Lifetime
- 2002-02-01 CN CNB028047516A patent/CN1265786C/zh not_active Expired - Lifetime
- 2002-02-01 DK DK02714140T patent/DK1359979T3/da active
- 2002-02-01 BR BR0206954-7A patent/BR0206954A/pt not_active Application Discontinuation
- 2002-02-01 WO PCT/EP2002/001042 patent/WO2002064214A2/en active IP Right Grant
- 2002-02-01 CA CA002435921A patent/CA2435921C/en not_active Expired - Lifetime
- 2002-02-01 KR KR1020037010445A patent/KR100542069B1/ko active IP Right Grant
- 2002-02-01 EP EP02714140A patent/EP1359979B1/en not_active Expired - Lifetime
- 2002-02-01 MX MXPA03007036A patent/MXPA03007036A/es active IP Right Grant
- 2002-02-01 AU AU2002246080A patent/AU2002246080B2/en not_active Expired
- 2002-02-01 PT PT02714140T patent/PT1359979E/pt unknown
- 2002-02-01 AT AT02714140T patent/ATE324145T1/de active
- 2002-02-07 AR ARP020100400A patent/AR035429A1/es not_active Application Discontinuation
-
2003
- 2003-08-01 ZA ZA2003/05967A patent/ZA200305967B/en unknown
-
2014
- 2014-12-12 AR ARP140104645A patent/AR098745A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR098745A2 (es) | 2016-06-08 |
US20020156118A1 (en) | 2002-10-24 |
DE60210926D1 (de) | 2006-06-01 |
CN1491126A (zh) | 2004-04-21 |
BR0206954A (pt) | 2004-02-25 |
CA2435921A1 (en) | 2002-08-22 |
WO2002064214A3 (en) | 2003-05-30 |
ATE324145T1 (de) | 2006-05-15 |
EP1359979B1 (en) | 2006-04-26 |
DE60210926T2 (de) | 2007-01-11 |
WO2002064214A8 (en) | 2004-02-19 |
ES2261648T3 (es) | 2006-11-16 |
ZA200305967B (en) | 2005-01-26 |
CN1265786C (zh) | 2006-07-26 |
WO2002064214A2 (en) | 2002-08-22 |
PT1359979E (pt) | 2006-08-31 |
EP1359979A2 (en) | 2003-11-12 |
JP4128872B2 (ja) | 2008-07-30 |
CA2435921C (en) | 2009-12-22 |
AU2002246080C1 (en) | 2002-08-28 |
KR20040025894A (ko) | 2004-03-26 |
MXPA03007036A (es) | 2003-11-18 |
JP2004517961A (ja) | 2004-06-17 |
AU2002246080B2 (en) | 2006-08-10 |
US6548531B2 (en) | 2003-04-15 |
KR100542069B1 (ko) | 2006-01-11 |
DK1359979T3 (da) | 2006-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098745A2 (es) | Composición, kit y uso de compuestos quimioterapéuticos | |
JP6280546B2 (ja) | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 | |
JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
ES2255287T3 (es) | Composiciones para el tratamiento de la leucemia linfocitica cronica. | |
JP2021059579A (ja) | 癌を処置するための医薬組合せ | |
ES2705529T3 (es) | Tratamiento combinatorio del cáncer | |
RU2010147287A (ru) | Комбинированная композиция | |
JP2016519684A (ja) | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 | |
EA201490477A1 (ru) | Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина | |
EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
SV2002000250A (es) | Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
ES2866933T3 (es) | Regímenes de dosificación de amisulprida para tratar náuseas y vómitos | |
SV2002000969A (es) | Composicion parenteral reconstituible | |
ES2441593T3 (es) | Composiciones para estimular la actividad de terapias anticáncer | |
UY28271A1 (es) | Compuestos químicos | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
UY28366A1 (es) | Compuestos químicos | |
ES2656913T3 (es) | Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes | |
AR033390A1 (es) | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes | |
RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
ES2267841T3 (es) | Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer. | |
JP6557253B2 (ja) | 抗腫瘍化合物としてのシグマ−2受容体リガンド薬物結合体、その合成法及び使用 | |
PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
ES2278702T3 (es) | Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |